Novavax, Inc.
NASDAQ:NVAX
Overview | Financials
Company Name | Novavax, Inc. |
Symbol | NVAX |
Currency | USD |
Price | 8.55 |
Market Cap | 1,369,581,750 |
Dividend Yield | 0% |
52-week-range | 3.53 - 23.86 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Charles Jacobs M.B.A. |
Website | https://www.novavax.com |
An error occurred while fetching data.
About Novavax, Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD